Acasti Pharma Cash Flow from Investing Activities 2014-2024 | GRCE
Acasti Pharma cash flow from investing activities from 2014 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
Acasti Pharma Annual Cash Flow Investing
(Millions of US $) |
| 2024 |
$0 |
| 2023 |
$13 |
| 2022 |
$-4 |
| 2021 |
$-10 |
| 2020 |
$8 |
| 2019 |
$-9 |
| 2018 |
$-0 |
| 2017 |
$5 |
| 2016 |
$6 |
| 2015 |
$7 |
| 2015 |
$ |
| 2014 |
$-19 |
| 2014 |
$ |
| 2013 |
$2 |
| 2013 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.031B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
